Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PSORS1
MCID: PSR023
MIFTS: 52

Psoriasis 1 (PSORS1)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Psoriasis 1

About this section

MalaCards integrated aliases for Psoriasis 1:

Name: Psoriasis 1 56 12 73 15
Psoriasis Susceptibility 1 56 29 13 6
Psoriasis Vulgaris 73 17 71 32
Psors1 56 12 73
Psoriasis 73 71
Psoriasis, Susceptibility to, Type 1 39
Psoriasis 1, Susceptibility to 56
Pv 73

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
prevalence 1-2% in northern european populations
onset bimodal, ages 16-22 and ages 57-60
inflammatory arthritis may develop in 30% of patients
types of psoriasis include - plaque, guttate, erythrodermic, pustular
environmental triggers include (koebner's phenomenon), sunburn, hiv infection, beta-hemolytic streptococcal infection, certain medications, stress, and alcohol


HPO:

31
psoriasis 1:
Inheritance multifactorial inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0111286
OMIM 56 177900
OMIM Phenotypic Series 56 PS177900
MeSH 43 D011565
ICD10 32 L40.0
MedGen 41 C1867449
SNOMED-CT via HPO 68 3723001 89704006 9014002
UMLS 71 C0033860 C0263361
Sources

Summaries for Psoriasis 1

About this section
OMIM : 56 Psoriasis (psoriasis vulgaris; PV) is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. The usual age of onset of psoriasis is between 15 and 30 years, although it can present at any age (summary by Matthews et al., 1996). Generalized pustular psoriasis (GPP) is a life-threatening disease characterized by sudden, repeated episodes of high-grade fever, generalized rash, and disseminated pustules, with hyperleukocytosis and elevated serum levels of C-reactive protein (123260) (summary by Marrakchi et al., 2011). GPP often presents in patients with existing or prior psoriasis vulgaris; however, GPP can develop without a history of PV (Sugiura et al., 2013). Palmoplantar pustulosis and acrodermatitis continua of Hallopeau represent acral forms of pustular psoriasis that have historically been grouped with GPP (summary by Setta-Kaffetzi et al., 2013). Nestle et al. (2009) provided a detailed review of the pathogenesis and genetics of psoriasis. (177900)

MalaCards based summary : Psoriasis 1, also known as psoriasis susceptibility 1, is related to psoriasis 4 and psoriasis 8, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 1 is HLA-C (Major Histocompatibility Complex, Class I, C), and among its related pathways/superpathways are Cellular senescence (KEGG) and Keratinization. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are arthritis and psoriasiform dermatitis

Disease Ontology : 12 A psoriasis that has material basis in variation in HLA-C on chromosome 6p21.33.

UniProtKB/Swiss-Prot : 73 Psoriasis 1: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

Sources

Related Diseases for Psoriasis 1

About this section

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1284)
# Related Disease Score Top Affiliating Genes
1 psoriasis 4 33.4 LCE3C LCE3B LCE3A HLA-C CDSN CARD14
2 psoriasis 8 33.3 TCF19 PSORS1C3 PSORS1C1 CDSN CARD14
3 psoriasis 2 32.1 LCE3C LCE3B CARD14
4 psoriasis 11 32.1 LCE3D IL23R
5 spondyloarthropathy 1 32.1 IL23R HLA-B CCR6
6 guttate psoriasis 30.8 HLA-C CDSN
7 alopecia areata 30.5 MICA HLA-C HLA-B
8 pustulosis of palm and sole 30.5 CCR6 CARD14
9 nail disease 30.5 TRAF3IP2 IL23R CCR6
10 spondylitis 30.5 MICA IL23R HLA-C HLA-B CCR6
11 spondyloarthropathy 30.4 HLA-C HLA-B CCR6
12 psoriasis 5 30.3 PSORS1C3 HLA-C CDSN CARD14
13 psoriasis 3 30.3 PSORS1C3 CDSN CCHCR1 CARD14
14 pityriasis rosea 30.3 HLA-C HLA-B
15 stevens-johnson syndrome/toxic epidermal necrolysis 30.0 PSORS1C1 HLA-C HLA-B
16 histoplasmosis 30.0 MICA HLA-B CCR6
17 skin disease 30.0 HLA-C HLA-B CDSN CCR6 CARD14
18 psoriasis 6 29.9 PSORS1C3 IL23R CDSN CCHCR1 CARD14
19 celiac disease 1 29.9 MICA IL23R HLA-C HLA-B CCR6
20 iritis 29.8 HLA-B CCR6
21 severe cutaneous adverse reaction 29.7 PSORS1C1 HLA-C HLA-B
22 peeling skin syndrome 29.7 TCF19 PSORS1C2 PSORS1C1 CDSN
23 epstein-barr virus hepatitis 29.6 HLA-C HLA-B
24 panuveitis 29.6 IL23R HLA-B CCR6
25 psoriasis 9 29.4 TCF19 PSORS1C3 LCE3C LCE3B CDSN CARD14
26 chronic mucocutaneous candidiasis 29.3 TRAF3IP2 IL23R CCR6
27 psoriasis 10 29.3 PSORS1C3 LCE3D LCE3C LCE3A CDSN CCHCR1
28 psoriasis 7 29.0 TCF19 PSORS1C3 PSORS1C1 IL23R CDSN CCHCR1
29 behcet syndrome 28.8 MICA IL23R HLA-C HLA-B CCR6
30 psoriatic arthritis 28.0 TRAF3IP2 TNIP1 MICA LCE3C LCE3B IL23R
31 psoriasis 26.5 TRAF3IP2 PSORS1C3 PSORS1C2 PSORS1C1 MICA LCE3C
32 pustular psoriasis 12.7
33 psoriasis 15, pustular 12.6
34 psoriasis 12 12.6
35 psoriasis 15 12.5
36 polycythemia vera 12.5
37 mental retardation and psoriasis 12.3
38 pustulosis palmaris et plantaris 12.3
39 tranebjaerg svejgaard syndrome 12.1
40 psoriatic juvenile idiopathic arthritis 11.9
41 impetigo herpetiformis 11.8
42 juvenile rheumatoid arthritis 11.7
43 geographic tongue 11.6
44 pemphigus 11.6
45 parapsoriasis 11.6
46 pemphigus vulgaris, familial 11.6
47 arthritis 11.5
48 persistent vegetative state 11.5
49 pulmonary valve stenosis 11.5
50 vitiligo-associated multiple autoimmune disease susceptibility 1 11.5

Graphical network of the top 20 diseases related to Psoriasis 1:



Diseases related to Psoriasis 1
Sources

Symptoms & Phenotypes for Psoriasis 1

About this section

Human phenotypes related to Psoriasis 1:

31
# Description HPO Frequency HPO Source Accession
1 arthritis 31 HP:0001369
2 psoriasiform dermatitis 31 HP:0003765
3 nail pits 31 HP:0001803
4 onychomadesis 31 HP:0025088

Symptoms via clinical synopsis from OMIM:

56
Skin Nails Hair Nails:
onycholysis
onychomadesis
nail pitting
dystrophic nail changes

Skin Nails Hair Skin:
red, raised, scaly skin patches (elbows, knees, scalp)

Immunology:
hla antigens cw6, b13, b17 associated with psoriasis

Skeletal:
arthritis (large joints, small joint, or central axial skeleton)

Skin Nails Hair Skin Histology:
lymphocytic inflammatory infiltrate
epidermal hyperproliferation
abnormal keratinocyte differentiation
koebner phenomenon

Clinical features from OMIM:

177900

UMLS symptoms related to Psoriasis 1:


pruritus, exanthema, psoriasiform rash
Sources

Drugs & Therapeutics for Psoriasis 1

About this section

Drugs for Psoriasis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 440)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
carbamide peroxide Approved Phase 4 124-43-6
6
Desoximetasone Approved Phase 4 382-67-2 5311067
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Clocortolone Approved Phase 4 4828-27-7, 34097-16-0 5282493 5311052
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
11 Strawberry Approved Phase 4
12 Orange Approved Phase 4
13 Artichoke Approved Phase 4
14
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
15
Abatacept Approved Phase 4 332348-12-6 10237
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18 Brodalumab Approved, Investigational Phase 4 1174395-19-7
19
Metformin Approved Phase 4 657-24-9 14219 4091
20
Ustekinumab Approved, Investigational Phase 4 815610-63-0
21 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
22 Vedolizumab Approved Phase 4 943609-66-3
23
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
24
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
25
Tofacitinib Approved, Investigational Phase 4 477600-75-2
26
Adalimumab Approved Phase 4 331731-18-1 16219006
27
Certolizumab pegol Approved Phase 4 428863-50-7
28
Mercaptopurine Approved Phase 4 50-44-2 667490
29
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35 Retinol palmitate Phase 4
36 retinol Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Omega 3 Fatty Acid Phase 4
39 Chelating Agents Phase 4
40 Halobetasol Phase 4
41 Tin Fluorides Phase 4
42 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
43
Chondroitin Phase 4 9007-27-6 53477707
44 Clocortolone pivalate Phase 4
45 Olive Phase 4
46 Citrate Phase 4
47 diuretics Phase 4
48 Anticoagulants Phase 4
49 Lidocaine, Prilocaine Drug Combination Phase 4
50 Pyrithione zinc Phase 4

Interventional clinical trials:

(show top 50) (show all 1686)
# Name Status NCT ID Phase Drugs
1 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
2 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
3 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
4 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
5 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
6 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
7 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
8 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
9 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
10 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
11 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
12 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
13 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
14 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
15 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
16 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
17 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
18 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
19 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
20 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
21 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
22 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
23 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
24 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
25 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
26 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam
27 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
28 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
29 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
30 A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Completed NCT01761019 Phase 4 Taclonex Topical Suspension
31 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
32 A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis Completed NCT00990561 Phase 4 Ultravate ointment twice daily + LacHydrin lotion twice daily;Ultravate ointment once daily + LacHydrin lotion twice daily
33 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
34 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
35 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
36 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
37 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
38 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
39 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
40 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
41 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
42 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
43 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
44 A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis Completed NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
45 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
46 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
47 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
48 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
49 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
50 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray

Search NIH Clinical Center for Psoriasis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen
Sources

Genetic Tests for Psoriasis 1

About this section

Genetic tests related to Psoriasis 1:

# Genetic test Affiliating Genes
1 Psoriasis Susceptibility 1 29 HLA-C
Sources

Anatomical Context for Psoriasis 1

About this section

MalaCards organs/tissues related to Psoriasis 1:

40
Skin, Testes, T Cells, Liver, Bone, Endothelial, Monocytes
Sources

Publications for Psoriasis 1

About this section

Articles related to Psoriasis 1:

(show top 50) (show all 204)
# Title Authors PMID Year
1
Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. 61 56 6
16642438 2006
2
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. 56 61
22521419 2012
3
Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. 61 56
19525279 2009
4
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. 61 56
16235096 2005
5
Mapping of the major psoriasis-susceptibility locus (PSORS1) in a 70-Kb interval around the corneodesmosin gene (CDSN). 56 61
15529278 2005
6
Transgenic mouse models support HCR as an effector gene in the PSORS1 locus. 61 56
15190014 2004
7
Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. 61 56
12648227 2003
8
Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. 61 56
12485440 2002
9
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. 61 56
12148091 2002
10
Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. 56 61
11875053 2002
11
The HCR gene on 6p21 is unlikely to be a psoriasis susceptibility gene. 61 56
11348465 2001
12
Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. 56 61
11134234 2001
13
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. 56 61
10801386 2000
14
Familial psoriasis and HLA-B: unambiguous support for linkage in 97 published families. 61 56
9694251 1998
15
Clinical improvement in psoriasis with specific targeting of interleukin-23. 56
25754330 2015
16
The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. 56
23698098 2013
17
Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. 56
23303454 2013
18
Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. 56
21848462 2011
19
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. 56
20953190 2010
20
Cutting edge: A critical functional role for IL-23 in psoriasis. 56
20956338 2010
21
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. 56
19684581 2009
22
Psoriasis. 56
19641206 2009
23
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. 56
18923449 2009
24
Psoriasis is associated with increased beta-defensin genomic copy number. 56
18059266 2008
25
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. 56
17873860 2007
26
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. 56
17603494 2007
27
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. 56
17287478 2007
28
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). 56
16380428 2005
29
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. 56
16163348 2005
30
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. 56
14981113 2004
31
The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. 56
12851855 2003
32
Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. 56
12588373 2003
33
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. 56
12461524 2003
34
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. 56
11841557 2002
35
Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. 56
11851889 2002
36
Interleukin-10 promoter polymorphism in psoriasis. 56
11407990 2001
37
Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. 56
11556968 2001
38
HLA-C and guttate psoriasis. 56
11122018 2000
39
The OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602. 56
11069619 2000
40
A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. 56
10888604 2000
41
Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. 56
10577939 1999
42
Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. 56
10545595 1999
43
Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. 56
10469328 1999
44
Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. 56
10332047 1999
45
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. 56
10225967 1999
46
Psoriasis linkage in the HLA region. 56
10053024 1999
47
Vitamin D receptor polymorphism is associated with psoriasis. 56
9886274 1999
48
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. 56
9858851 1999
49
Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. 56
9634500 1998
50
The role of T-cell costimulatory activation pathways in transplant rejection. 56
9632449 1998
Sources

Variations for Psoriasis 1

About this section

ClinVar genetic disease variations for Psoriasis 1:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HLA-C HLA-C, HLA-Cw6undetermined variant risk factor 14906
Sources

Expression for Psoriasis 1

About this section
Search GEO for disease gene expression data for Psoriasis 1.
Sources

Pathways for Psoriasis 1

About this section

Pathways related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cellular senescence (KEGG) 36
11.63 TRAF3IP2 HLA-C HLA-B
2
Keratinization 65
Show member pathways
 11.48 LCE3D LCE3C LCE3B LCE3A CDSN
3
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
11.26 MICA HLA-C HLA-B
4
Antigen Presentation- Folding, assembly and peptide loading of class I MHC 65
10.55 HLA-C HLA-B
Sources

GO Terms for Psoriasis 1

About this section

Cellular components related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class I protein complex GO:0042612 8.62 HLA-C HLA-B

Biological processes related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.58 LCE3C LCE3B LCE3A
2 defense response to Gram-negative bacterium GO:0050829 9.46 LCE3C LCE3B LCE3A IL23R
3 positive regulation of T cell mediated cytotoxicity GO:0001916 9.43 IL23R HLA-B
4 killing of cells of other organism GO:0031640 9.43 LCE3C LCE3B LCE3A
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.37 HLA-C HLA-B
6 keratinization GO:0031424 9.35 SPRR4 LCE3D LCE3C LCE3B LCE3A
7 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.32 HLA-C HLA-B
8 epidermis development GO:0008544 9.02 LCE3D LCE3C LCE3B LCE3A CDSN

Molecular functions related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TAP binding GO:0046977 8.62 HLA-C HLA-B
Sources

Sources for Psoriasis 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....